// added the section below on July 01 2024 // till here on July 01 2024

Immune Checkpoint Inhibitors Market

Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025

  • Lowest Price Guaranteed From USD 2,199

  • Pages

  • View Count

Immune Checkpoint Inhibitors Market Overview

The global immune checkpoint inhibitors market is likely to be worth $25 billion by 2025. Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body’s own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). Interest has surged in other classes of immunotherapeutics; these include Immune Checkpoint Inhibitors, therapeutic cancer vaccines and other whole cell based therapies.

Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in immune checkpoint inhibitors market, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and many under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform.With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period.

In addition to the marketed drugs (Yervoy, Opdivo and Keytruda), we expect a number of drugs currently in advanced stages of development (Tremelimumab, Elotuzumab, RG7446 and Avelumab)to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

Recent Developments in Next Generation Immune Checkpoint Inhibitors Market:

Several recent developments have taken place in the field of next generation immune checkpoint inhibitors market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In October 2023, iOmx Therapeutics presented a data on target discovery platform Myeloid iOTarg™ and new data on SIK checkpoint inhibitor OMX-0407 at AACR 2023.

Scope of the Report

The “Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025” market report provides a comprehensive analysis of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the immune checkpoint inhibitors market. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic commercially available until other classes recently stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the immune checkpoint inhibitors market.

In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which have recently gained ground and are expected to retain attention in the future.

One of the key objectives of the market research report is to review the prospects laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With three marketed drugs (Yervoy, Keytruda and Opdivo), the market is treading its way towards fulfilling the huge untapped promise. Amongst other elements, the market research report elaborates upon the following key areas:

  • The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted
  • Recent partnerships which have taken place over the last five years including product co-development, licensing and clinical trial collaborations
  • Combinationtherapies where Immune Checkpoint Inhibitors are being evaluated in combination with other anti-cancer agents/therapies
  • Various investments and grants received by the companies focused in this area
  • Competitive landscape and inherent threats to growth in the short and long term
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The key objective of immune checkpoint inhibitors market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for immune checkpoint inhibitors market during the forecast period. The research, analysis and insights presented in this market report include potential sales of several Immune Checkpoint Inhibitors; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.All actual figures have been sourced and analyzed from publicly available information. The figures mentioned in this market research report are in USD, unless otherwise specified.


This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com